In this episode, we explore a groundbreaking leap in cancer detection—one that may save millions of lives through early screening. Imagine a world where a single blood test could detect over 50 types of cancer, including those that are often diagnosed too late, like pancreatic, ovarian, and lung cancers. The Galleri Test, developed by GRAIL, offers a revolutionary approach to identifying cancer in its earliest stages when treatment is most effective.
Dr. Gabiola, who tragically lost her husband to pancreatic cancer at just 46, takes us through her deeply personal connection to this issue. She shares how her experiences led to a quest for better early detection methods, especially for cancers that hide until they’re advanced. Now, the Galleri test, a non-invasive blood test, presents new hope for patients, detecting cancer signals long before symptoms appear.
Dr. Josh Ofman, the President of GRAIL, explains how the Galleri test uses advanced AI to detect cancer DNA in the blood, offering a 90% accuracy rate for identifying the origin of the cancer signal. This multi-cancer screening is set to complement existing tests like mammograms and colonoscopies, but its broad scope may significantly reduce cancer mortality rates in the future. For those at risk or over the age of 50, this test represents a monumental shift in preventive care.
Listen in as we unpack the science behind this innovation, the future of early cancer detection, and the impact it could have on individuals and their families.
Mentioned in the Show:
- GRAIL's Website (Galleri Test Information): Dr. Ofman referenced that patients and providers can learn more about the Galleri test on GRAIL's website. He also mentioned that individuals can order the test through telemedicine providers from this site: GRAIL (Galleri Test)
- Quest Labs: For those who order the Galleri test, they can visit a Quest Labs location to have their blood drawn for the test: Quest Diagnostics
About Dr. Josh Ofman, MD, MSHS
Josh Ofman, MD, MSHS, is President at GRAIL. Josh also serves on the Board of Directors of Cell BT, Inc, an immuno-therapy company focused on the discovery and development of innovative cancer therapeutics. Previously, Josh spent more than 15 years at Amgen, where he most recently held the role of Senior Vice President, Global Value, Access and Policy.
Prior to that, Josh was a faculty member in the Department of Medicine and Health Services Research at University of California, Los Angeles (UCLA) School of Medicine, Cedars-Sinai Medical Center, as well as Senior Vice President of Zynx Health Inc., a subsidiary of Cerner Corp.
Josh holds a BA in history and philosophy of science from the University of California, Berkeley, and an MD from the University of California, Irvine, School of Medicine. Josh also has an MSHS from the UCLA School of Public Health.
About the Host:
Dr. Jette is a Clinical Professor of Medicine at Stanford University and the President & CEO of ABCs for Global Health. Click here for her full profile or read her full interview here.
Hosted on Acast. See acast.com/privacy for more information.